Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.
Date | Price Target | Rating | Analyst |
---|---|---|---|
7/3/2025 | $12.00 | Overweight | Morgan Stanley |
3/18/2025 | $5.00 | Mkt Perform → Mkt Outperform | Citizens JMP |
3/14/2025 | $7.00 | Buy | Jefferies |
1/8/2025 | Hold → Buy | TD Cowen | |
11/5/2024 | Mkt Outperform → Mkt Perform | JMP Securities | |
6/26/2024 | $16.00 | Buy | Rodman & Renshaw |
1/16/2024 | $12.00 | Neutral → Buy | H.C. Wainwright |
9/25/2023 | $9.00 | Mkt Outperform | JMP Securities |
4 - Sana Biotechnology, Inc. (0001770121) (Issuer)
4 - Sana Biotechnology, Inc. (0001770121) (Issuer)
4 - Sana Biotechnology, Inc. (0001770121) (Issuer)
Myles, a Biopharma Industry Veteran, Will Also Join Flagship Pioneering as a CEO-Partner CAMBRIDGE, Mass., May 12, 2025 /PRNewswire/ -- Cellarity, a life sciences company transforming the way medicines are created, and Flagship Pioneering, the bioplatform innovation company, today announced the appointment of Ted Myles as Chief Executive Officer of Cellarity and CEO-Partner at Flagship. Myles is a seasoned biopharma leader with deep experience and a track record for building clinical and commercial-stage companies. Previously, he was Chief Financial Officer and Chief Operating
CAMBRIDGE, Mass., April 29, 2025 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, and Quotient Therapeutics, a company pioneering somatic genomics, today announced that Rahul Kakkar, M.D., will join Flagship Pioneering as CEO-Partner and Quotient Therapeutics as Chief Executive Officer. Dr. Kakkar is a biotech entrepreneur and physician-scientist with nearly 20 years of professional experience founding and building biotechnology companies and practicing medicine. Previously, he served as President and CEO of Tome Biosciences, a genome engineering biotec
Announced positive preliminary 12-week clinical results, building on already released 4-week results, of ongoing type 1 diabetes study showing that hypoimmune-modified pancreatic islet cells transplanted without immunosuppression overcome autoimmune and allogeneic immune recognition, function, and persist with stable C-peptide production post-transplant Enrolling patients in the GLEAM trial for SC291 in B-cell mediated autoimmune diseases and VIVID trial for SC262 in relapsed/refractory B-cell malignancies; expect to report clinical data from both studies in 2025 Presented preclinical data in non-human primates showing safety and deep B cell depletion using a surrogate for SG299, an in viv
Morgan Stanley resumed coverage of Sana Biotechnology with a rating of Overweight and set a new price target of $12.00
Citizens JMP upgraded Sana Biotechnology from Mkt Perform to Mkt Outperform and set a new price target of $5.00
Jefferies initiated coverage of Sana Biotechnology with a rating of Buy and set a new price target of $7.00
Solutions focus on enhancing crop resilience, protecting yields, and addressing critical challenges in the global food system The company emerges after four years of platform development with an initial commitment of $50 million from Flagship Pioneering CAMBRIDGE, Mass., July 1, 2025 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, today unveiled Terrana Biosciences™, a company pioneering RNA-based agricultural solutions to deliver protective and enhanced crop traits without altering the plant genome. Through its proprietary RNA technology platform, Terrana is developing targeted products designed to work at any time in a plant's lifecycle, enabling a continuous prod
SEATTLE, June 09, 2025 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ:SANA), a company focused on changing the possible for patients through engineered cells, today announced an upcoming podium presentation highlighting ongoing clinical data from the investigator-sponsored, first-in-human study transplanting UP421, an allogeneic primary islet cell therapy engineered with Sana's hypoimmune (HIP) technology, into a patient with type 1 diabetes without the use of any immunosuppression. The presentation will be held during a joint American Diabetes Association (ADA)/International Pancreas & Islet Transplant Association (IPITA) symposium at the 85th Annual ADA Scientific Sessions taking p
SEATTLE, May 28, 2025 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ:SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentations at two investor conferences in June. The presentations will feature a business overview and update. Sana will present at the Jefferies Global Healthcare Conference at 2:35 p.m. ET on Wednesday, June 4, 2025.Sana will present at the Goldman Sachs 46th Annual Global Healthcare Conference at 8:40 a.m. ET on Tuesday, June 10, 2025. The webcasts will be accessible on the Investor Relations page of Sana's website at https://sana.com/. A replay of each presentation will be availa
8-K - Sana Biotechnology, Inc. (0001770121) (Filer)
8-K - Sana Biotechnology, Inc. (0001770121) (Filer)
424B5 - Sana Biotechnology, Inc. (0001770121) (Filer)
4 - Sana Biotechnology, Inc. (0001770121) (Issuer)
4 - Sana Biotechnology, Inc. (0001770121) (Issuer)
4 - Sana Biotechnology, Inc. (0001770121) (Issuer)
First-in-Human Study Provides Evidence that Sana's Hypoimmune (HIP) Technology Enables Transplanted Islet Cells to Avoid Immune Rejection and Produce Insulin Without Immunosuppression Results Demonstrate HIP-Engineered Primary Pancreatic Islet Cells Avoid Immune Detection, Function, and Persist after Intramuscular Transplantation in First Treated Patient with Type 1 Diabetes Function and Persistence of Pancreatic Islets Were Detectable by Production of Consistent Levels of Circulating C-Peptide, a Marker of Insulin Production, and Increased C-Peptide Levels with a Mixed Meal Tolerance Test (MMTT) MRI Shows Signals Consistent with Graft Survival 28 Days after Transplantation Study Contin
SC 13G/A - Sana Biotechnology, Inc. (0001770121) (Subject)
SC 13G/A - Sana Biotechnology, Inc. (0001770121) (Subject)
SC 13G/A - Sana Biotechnology, Inc. (0001770121) (Subject)